REG - e-Therapeutics plc - Director Dealing and Issue of Equity

E-TherapeuticsAnnouncement

04/01/2023 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230104:nRSD7036La&default-theme=true

RNS Number : 7036L  e-Therapeutics plc  04 January 2023

E-THERAPEUTICS PLC

 

("e-therapeutics" or the "Company")

 

DIRECTOR DEALING AND ISSUE OF EQUITY

 

London, UK, 4 January 2023 - e-therapeutics plc (AIM: ETX), the drug
discovery company, announces that on 4 January 2023, Professor Trevor Jones
(Non-Executive Chairman of the Company) subscribed for a total of 44,350 new
ordinary shares of 0.1p each in the Company (the "New Ordinary Shares") at a
price of 17.05 pence per share. The subscription monies paid for the New
Ordinary Shares represent 50% of Professor Jones' Non-Executive Director fees
net of tax paid during the period from 1 July 2022 to 31 December 2022 in
accordance with the agreement entered into with Professor Jones, previously
announced on 5 October 2016, by which Professor Jones agreed, with effect from
1 October 2016, to invest 50% of his annual Non-Executive Director fees net of
tax in new e-therapeutics' ordinary shares. Such new shares are issued to
Professor Jones on the first business day after 31 December and 30 June in
each year. The subscription price to be paid is the average of the closing
mid-market price for the five business days prior to the date of issue.

 

Following Admission, Professor Jones will be interested in a total of
1,167,741 ordinary shares of 0.1p in the Company, representing approximately
0.20% of the Company's issued share capital.

 

Application has been made to AIM for the admission of the New Ordinary Shares
to trading on AIM ("Admission") and Admission is expected to occur at 8:00
a.m. on or around 11 January 2023. The New Ordinary Shares will rank pari
passu in all respects with the Company's existing ordinary shares in issue.

 

Following Admission, the total number of ordinary shares in the Company with
voting rights in issue will be 582,159,332. This figure may be used by
shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the Company under the Financial Conduct Authority's
Disclosure and Transparency Rules.

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further details:

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Trevor Jones
 2   Reason for the notification
 a)  Position/status                                              Non-Executive Chairman
 b)  Initial notification/ Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         e-therapeutics plc
 b)  LEI                                                          21380049RHSSJXWKYT18
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of 0.1 pence

     Identification code

                                                                  ISIN: GB00B2823H99
 b)  Nature of the transaction                                    Purchase of shares
 c)  Price(s) and volume(s)                                       44,350 ordinary shares at a price of 17.05 pence per share
 d)  Aggregated information                                       44,350 ordinary shares

     - Aggregated volume                                          17.05 pence per share

     - Price                                                      Aggregated value: £7,561.76

 e)  Date of the transaction                                      4 January 2023

 f)  Place of the transaction                                     Outside a trading venue

 

 

For further information, please contact:

 

 e-therapeutics plc
 Ali Mortazavi,                                                                        Tel: +44 (0)1993 883 125
 CEO

                                                                                     www.etherapeutics.co.uk
 James Chandler, VP IR & Communications

      SP Angel Corporate Finance LLP                                                   Tel: +44(0)20 3470 0470
 Nominated Adviser and Broker
 Matthew Johnson/Harry Davies-Ball (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc

 

About e-therapeutics plc

 

e-therapeutics plc ("ETX") integrates computational power and biology
information to discover life-transforming RNAi medicines.  The Company's
technology uses computation to capture and model human biology, identify
novel targets and develop RNAi medicines against those targets that can be
rapidly progressed to the clinic.

 

ETX's proprietary Computational Biology Platform enables the generation and
analysis of biological network models, providing a novel and mechanistic
approach to drug discovery that explicitly considers the true complexity of
biology and makes more reliable predictions from large complex data sets and
ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive
and integrated hepatocyte-centric data and information resource.  The Company
generates, prioritises and tests millions of hypotheses in silico to identify
better therapeutic targets with higher confidence.

 

ETX's proprietary RNAi Platform enables the targeted delivery to hepatocytes
in the liver and the specific silencing of novel disease-associated genes,
identified by ETX's Computational Biology Platform.  The focus on hepatocytes
offers the opportunity to work across a wide variety of diseases.  The liver
is a highly metabolically active organ which performs a key role in many
biological processes and vital functions crucial for human health.
ETX's GalNAc-siRNA constructs have demonstrated compelling in vivo
performance in terms of depth of gene silencing and duration of action.

 

ETX is progressing a pipeline of first-in-class pre-clinical RNAi candidates
in several therapeutic areas including haematology, cardiovascular disease
and non-alcoholic steatohepatitis ("NASH").  ETX has also partnered with
biopharma companies such as Novo Nordisk, Galapagos NV and iTeos
Therapeutics using its computational network biology approach across a
diverse range of drug discovery projects.

 

The Company is based in London, UK and listed on the Alternative Investment
Market of the London Stock Exchange ("AIM"), with ticker symbol ETX.
e-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United
States, under ticker symbol ETXPF.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFLELVISIIV